Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Teva Pharmaceuticals' CEO advocates for quicker FDA generic drug approvals, which he argues would save the U.S. healthcare system money. Concurrently, the Trump administration has revised the number ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

The current health news highlights Abridge raising $250 million to boost AI medical documentation, layoffs involving ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Reports Q4 revenue $4.2B, consensus $4.12B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “2024 marked a transformative year for Teva, resulting in a second consecutive year of ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full year 2024 financial results.